Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.70    -0.15 (-5.26%)
Bid:
2.60
Ask:
2.70
Spread: 0.10 (3.846%)
Market Cap: £2.78m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Incentive Awards

29 Oct 2021 13:00

RNS Number : 7642Q
Litigation Capital Management Ltd
29 October 2021
 

29 October 2021

Litigation Capital Management Limited

("LCM" or the "Company")

 Incentive Awards

Litigation Capital Management Limited (AIM:LIT), a leading international alternate asset manager of disputes financing solutions, announces that on 27 October 2021 it granted a number of incentive awards to employees and directors of the Company either in the form of shares to be issued pursuant to the LCM Loan Share Plan ("LSP") or via the Company's share option plan.

The following table details the quantum of Awards granted and the recipients:

Employee

Position

Incentive Scheme

Number of Share/Options Awarded

Patrick Moloney

Chief Executive Officer

LSP

279,232

Mary Gangemi

Chief Financial Officer

Option awards

93,585

Mary Gangemi

Chief Financial Officer

CSOP

26,315

Non-PDMR Employees

Various

LSP

333,406

Non-PDMR Employees

Various

Option awards

223,491

Non-PDMR Employees

Various

CSOP

56,460

 

LCM Loan Share Plan ("LSP")

The Company has in place a LSP. Ordinary Shares issued to recipients under the LSP ("LSP Shares") generally rank equally with all existing shares from the date of issue.

The LSP Shares are issued to the recipient at market value and due to the vesting conditions attached to them (e.g. continuous employment conditions) represent a share based payment arrangement.

The LSP awards, unless stated otherwise, will vest over a three-year period in four equal tranches from the date of issue.

In addition, the LSP awards are subject to malus and clawback provisions. The awards vest in full in the event of a change of control at any time.

Option awards

The Company has in place a Company share option plan ("Option awards"). Options over Ordinary Shares are issued to recipients under the Option awards. The Option awards are issued to the recipient at market value and due to the vesting conditions attached to them (e.g. continuous employment conditions) represent a share based payment arrangement.

The Option awards, unless stated otherwise, will vest over a three-year period in four equal tranches from the date of issue.

 In addition, the Option awards are subject to malus and clawback provisions. The awards vest in full in the event of a change of control at any time.

Company share ownership plan ("CSOP")

 

The Company has in place a CSOP. Options over Ordinary Shares ("Options") are issued to recipients under the CSOP ("CSOP Options") at an exercise price being the share price on the day prior to close, subject to continued employment over the three year period.

 

The CSOP awards, unless stated otherwise, will vest at the end of a three-year period from the date of issue.

 

Admission of Shares

Application will be made for 612,638 ordinary shares to be admitted to trading on AIM. It is expected that admission will take place on 5 November 2021. Following the allotment and issue, the Company's issued share capital consists of 117,199,145ordinary shares. The Company does not hold any shares in Treasury, as such the total number of shares in issue with voting rights is 117,199,145.

The above figure 117,199,145may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

 

 

 

Alma PR

Tel: 020 3405 0205

Justine James

Kieran Breheny

Molly Gretton

LCM@almapr.co.uk

 

 

 

NOTES TO EDITORS

Litigation Capital Management (LCM) is an alternate asset manager specialising in disputes financing solutions internationally, which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is third party fund management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record driven by disciplined project selection and robust risk management.

Currently headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

www.lcmfinance.com

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Patrick John Moloney

2.

Reason for the notification

a)

Position / status

Executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Interest in Ordinary Shares under a Loan Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£1.06

279,232

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

N/A - single transaction

e)

Date of the transaction

27 October 2021 (UK)

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")

a)

Name

Mary Gangemi

2.

Reason for the notification

a)

Position / status

Executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Litigation Capital Management Limited

b)

Legal Entity Identifier

213800J2B5SI8F515244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Option over ordinary shares

b)

Nature of the transaction

Grant of option

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Award

£1.14

26,315

CSOP

£1.06

93,585

Option award

 

d)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

 

119,000 options over ordinary shares

e)

Date of the transaction

27 October 2021 (UK)

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBBDGIUDDGBC
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.